Sona Nanotech Inc., - CEO, Darren Rowles
CEO, Darren Rowles
Source: Inkwood Research
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Sona Nanotech (SONA) is launching a new research program to explore its proprietary gold nanorod technology
  • The company will collaborate with Dr. Warren Chan from the University of Toronto to conducts this research
  • Sona will use the data from this and future programs to identify the most promising medical applications for its technology
  • Sona Nanotech is a nanotechnology life sciences firm
  • Shares in Sona Nanotech Inc. (SONA) are up 3.37 per cent, trading at $0.46 per share

Sona Nanotech (SONA) is launching a new research program to explore its proprietary gold nanorod technology.

The company will collaborate with Dr. Warren Chan from the University of Toronto to conduct this research.

Dr. Chan serves as Canada Research Chair in Nanobioengineering and Director of the Institute of Biomedical Engineering at the University of Toronto.

Sona’s gold nanorod particles are CTAB (cetyltrimethylammonium) free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications.

Sona’s research collaborations will leverage the expertise and scientific leadership of a group of third-party, respected scientists and entrepreneurs to work with Sona’s team.

Under this research agreement, Sona will consult with Dr. Chan on the design and execution of studies that will determine the biocompatibility of the proprietary technology.

“The biocompatibility of nanomaterials will be an important component to the unlocking of new, potentially life-saving, medical nanotechnology applications,” said Dr. Chan, “and so our study will explore Sona Nanotech’s gold nanorods as a safe, non-toxic material for use ‘in-vivo’.”

This research program will provide a foundation for future programs, which Sona will use to identify the most promising medical applications for its technology.

Darren Rowles, president and Chief Scientific Officer of Sona, commented on the research collaboration.

“We are delighted to be working with Dr. Chan, one of the most important nanotechnology scientists in the world, and we are excited to explore with him the unique attributes and benefits our technology may bring to enabling new, important biomedical applications.”

Sona Nanotech is a nanotechnology life sciences firm that has developed multiple proprietary methods for the manufacture of various types of gold nanoparticles.

Shares in Sona Nanotech Inc. (SONA) are up 3.37 per cent, trading at $0.46 per share as of 3:53 pm ET.

More From The Market Herald

" Micromem Technologies (CSE:MRM) closes private placement

Micromem Technologies (MRM) has closed a private placement for gross proceeds of $282,000.
PyroGenesis - Vice President of Sales, Massimo Dattilo.

" PyroGenesis (TSX:PYR) completes titanium powder order from Aubert & Duval

PyroGenesis (PYR) has completed a 100 kg titanium powder order from Aubert & Duval.

" Adamant Global Holdings (CSE:ADMT) releases 2021 results

Adamant (ADMT) has released its 2021 financial results headlined by significant revenue growth.

" Buzz on the Bullboards: The Larger the Hubs, the Heavier the Debates

Several of Stockhouse’s larger Bullboard hubs have set off serious debates on the future direction of some companies following significant moves this past